Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors.
Aminoguanidine decreases the formation of advanced glycosylation end products that occurs during chronic hyperglycemia. Presumably this occurs because early glycosylation products preferentially bind to aminoguanidine rather than to lysine groups of adjacent proteins. Because oxidative modification...
I tiakina i:
| I whakaputaina i: | Proc Natl Acad Sci U S A |
|---|---|
| Ngā kaituhi matua: | , , , |
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
National Academy of Sciences
1992
|
| Ngā marau: | |
| Urunga tuihono: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC49607/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1495978/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.89.15.6876 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|